Ergoteles’s NextCure NXTC Stock Holding History

Ergoteles’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,465	Closed	-$24.8K	–	1612
2022 Q4	$24.8K	Buy	+1,465	New	+$33.7K	﹤0.01%	1339
2021 Q4	–	Sell	-5,992	Closed	-$485K	–	1485
2021 Q3	$485K	Sell	5,992 -266	-4%	-$23.3K	0.02%	596
2021 Q2	$603K	Buy	+6,258	New	+$640K	0.01%	717

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Ergoteles's NXTC Position: Q1 2023 in Review

Ergoteles sold out of NextCure (NXTC) in Q1 2023, closing a stake of 1,465 shares — an estimated $24.8K sold.

Ergoteles first reported a position in NXTC in Q2 2021 and held it in 3 quarters. The position peaked at $603K in Q2 2021. 43 funds tracked by Wall St. Rank hold NXTC as of Q1 2023.

Ergoteles reported no remaining NextCure position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 1,465 NextCure shares in Q1 2023, an estimated $24.8K.
Ergoteles first reported a position in NextCure in Q2 2021 and held it in 3 quarters.
Ergoteles's NextCure position peaked at $603K in Q2 2021.
43 funds tracked by Wall St. Rank held NextCure as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.